摘要
替格瑞洛是新型的P2Y12受体抑制剂,在起效速度和疗效方面均优于氯吡格雷,广泛应用于冠心病急性冠脉综合征和PCI术后患者抗血小板聚集的治疗。但随着替格瑞洛的普遍使用,其相关呼吸困难不良反应报道也不断增加,然而临床上对导致此不良反应发生机制的研究结果存在异议。本文对替格瑞洛使用中呼吸困难发生现状和发生机制的研究进展进行综述,为临床合理用药提供参考。
Ticagrelor is an new P2Y12 receptor inhibitor,which is superior to clopidogrel in the onset speed and efficacy,which is widely used in treatment of acute coronary syndrome and anti platelet aggregation in patients after PCI.However with the widespread use of Ticagrelor,the adverse reactions related to dyspnea have been reported more and more.Moreover,there exist different opinions on the mechanism of the adverse reactions.This article is aimed to review the current situation and mechanism of dyspnea during the use of Ticagrelor,in order to provide reference for clinical rational use of drugs.
作者
陈玮
郭雪
李亚男
杨秀岭
CHEN Wei;GUO Xue;LI Yanan(The Second Hospital of Hebei Medical University,Hebei,Shijiazhuang 050000,China)
出处
《河北医药》
CAS
2021年第1期125-129,共5页
Hebei Medical Journal
